The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
Theo de Witte
Rena Buckstein
Silvia Magalhães
Yasushi MiyazakiThe MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena Buckstein, and featured Theo de Witte, Silvia Magalhães, and Yasushi Miyazaki. The topic of this discussion, “What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?”, was identified as an unmet educational need within MDS treatment.
What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
Buckstein begins by discussing two case studies, and the use of IPSS-R to define risk. De Witte talks about the effect that comorbidities can have on patient outcomes, and the committee discusses the treatment options and possible outcomes of the case study patients. Buckstein presents information on prognostic factors and the significance of mutations in prognosis. The committee also discusses how to calculate prognostic factors to decide treatment strategies, determine survival, and counsel patients. Buckstein then explains which genes are included in the IPSS-Molecular (IPSS-M) calculations. Finally, the committee discusses how the IPSS-M could be implemented in clinical settings, including potential problems.